> Research summary — not medical advice. This page synthesizes published research on a mechanism-level intervention. It is not a clinical recommendation. Consult a qualified healthcare provider before making any changes to diet, supplementation, or treatment.
Intervention Summary
Targeted restoration of Faecalibacterium prausnitzii — the most consistently depleted commensal across nearly every disease signature in the knowledge base (IBD, CRC, ASD, neuropsychiatric conditions, metabolic disease). F. prausnitzii is an obligate anaerobe that produces butyrate, secretes the microbial anti-inflammatory molecule (MAM), induces IL-10 from dendritic cells, and suppresses NF-kB signaling.
Evidence
- F. prausnitzii abundance inversely correlates with Crohn's disease relapse risk in prospective cohorts
- Post-surgical recurrence of CD is predicted by low F. prausnitzii counts at resection margins
- Animal models confirm oral F. prausnitzii reduces colitis severity and restores barrier function
- Direct human supplementation trials are in early stages — the organism's extreme oxygen sensitivity (dies within minutes of air exposure) makes formulation challenging
- Indirect restoration via prebiotic feeding (see high fiber prebiotics) is the current practical approach
Mechanism
- Butyrate production: F. prausnitzii is one of the top butyrate producers in the human colon, feeding colonocytes and maintaining the anaerobic lumen
- MAM secretion: The microbial anti-inflammatory molecule directly inhibits NF-kB in epithelial cells
- IL-10 induction: F. prausnitzii stimulates anti-inflammatory IL-10 production from dendritic cells
- Oxygen consumption: As an obligate anaerobe dependent on butyrate-driven colonocyte oxygen consumption, its restoration helps re-establish the steep oxygen gradient that maintains healthy anaerobic ecology
Clinical Context
Direct F. prausnitzii supplementation is not yet commercially available as a probiotic. Current strategies focus on indirect restoration through prebiotic substrates (inulin, resistant starch), FMT, or dietary interventions that support anaerobic ecology. Several biotech companies are developing encapsulated live biotherapeutic products. Until direct delivery is solved, practitioners should focus on creating the ecological conditions that favor F. prausnitzii colonization.
—-
> Educational content, not medical advice. This page describes mechanisms by which the intervention interacts with the microbiome and metal ecology. It is not a treatment recommendation. Clinical decisions about any intervention should be made with a qualified healthcare practitioner who knows your individual history.